Phase III study of adjuvant gemcitabine compared with adjuvant uracil-tegafur in patients with completely resected pathological stage IB –IIIA non-small cell lung cancer (WJTOG0101)

ConclusionAlthough GEM-based adjuvant therapy for patients with completely resected stage IB –IIIA NSCLC was associated with acceptable toxicity, it did not provide longer OS than did UFT.
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research